Altimmune, Inc.

Terns Pharmaceuticals, Inc.

Viking Therapeutics, Inc.

Following the meteoric success of Novo Nordisk and Eli Lilly’s semaglutide-based weight-loss injections, the obesity and metabolic disease treatment sector has drawn heightened investor attention. Since Ozempic was <a href="https://www.prnewswire.com/news-releases/novo-nordisk-receives-fda-approval-of-ozempic-semaglutide-injection-for-the-treatment-of-adults-with-type-2-diabetes-300567052.html">approved</a>&nbsp;in December 2017, Novo Nordisk’s stock has gained 125%, pushing its <a href="https://companiesmarketcap.com/novo-nordisk/marketcap/">market capitalization</a> to $252 billion. Eli Lilly, after launching <a href="https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-Zepboundtm-tirzepatide-chronic-weight">Zepbound</a>&nbsp;in November 2023, has seen its share price climb 23% and its <a href="https://companiesmarketcap.com/eli-lilly/marketcap/">market cap</a> reach $681 billion. Morgan Stanley <a href="https://www.morganstanley.com/insights/articles/weight-loss-medication-market-unstoppable-growth#:~:text=Morgan%2520Stanley%2520Research%2520now%2520estimates,about%2520%252415%2520billion%2520in%2520sales">estimates</a>&nbsp;the global market for obesity drugs could exceed $150 billion by 2035.

Small caps that can challenge Novo Nordisk and Eli Lilly in the obesity drug market

Eli Lilly and Company

Novo Nordisk A/S

Side effects of Viking's obesity pill upset investors

Viking shares fall 45% due to drug tests. Have the risks for Novo and Eli been reduced?

Tesla, Inc.

Intel Corporation

Daily review and forecast of events on the U.S. stock market from Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research.

Morning in New York: foreign policy agenda remains in the center of attention of the markets

Freedom Broker has issued a trade idea on the biotech Viking Therapeutics. The company is expected to present fresh data from clinical trials of its main weight-loss drug, and historically, as Freedom Broker points out, the stock rises ahead of these events.

Freedom Broker says buy weight-loss drugmaker Viking ahead of 2H data releases

Shares of the biopharmaceutical company Viking Therapeutics surged 21% on Thursday, October 24. The gains were attributable to released financial results for the third quarter, which showed that the company had sufficient financial resources to continue clinical trials for its promising weight-loss pill. If they are successful, Viking could eventually challenge current market leaders Novo Nordisk and Eli Lilly. Recall that earlier this month, Morgan Stanley included Viking in a list of small-cap stocks with at least 50% upside.

#Viking Therapeutics: 5

Small caps that can challenge Novo Nordisk and Eli Lilly in the obesity drug market

Viking shares fall 45% due to drug tests. Have the risks for Novo and Eli been reduced?

Morning in New York: foreign policy agenda remains in the center of attention of the markets

Freedom Broker says buy weight-loss drugmaker Viking ahead of 2H data releases

Potential Eli Lilly and Novo Nordisk competitor surges 21% on third-quarter financials